Commitments and Contingencies (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Sep. 30, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Commitments and Contingencies (Details) [Line Items] | |||
| Rent expense for space | $ 13,080 | ||
| Rent expense | $ 403,449 | $ 350,979 | |
| 2011 Exclusive Agreement [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Milestone payment | $ 765,000 | ||
| License reduced percentage | 50.00% | ||
| Aggregate maintenance fees | $ 80,000 | ||
| Maintenance fees annually | $ 50,000 | ||
| Royalty percentage | 2.00% | ||
| Minimum royalty expense | $ 75,000 | ||
| Royalty description | The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). | ||
| 2013 Exclusive Agreement [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Milestone payment | $ 765,000 | ||
| License reduced percentage | 50.00% | ||
| Aggregate maintenance fees | $ 7,500 | ||
| Maintenance fees annually | $ 5,000 | ||
| Royalty percentage | 2.00% | ||
| Minimum royalty expense | $ 75,000 | ||
| License costs | $ 10,000 | ||
| Royalty description | The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). | ||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs related to services rendered by an entity during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. No definition available.
|
| X | ||||||||||
- Definition Percentage of license reduced. No definition available.
|
| X | ||||||||||
- Definition Amount of maintenance. No definition available.
|
| X | ||||||||||
- Definition Description of the royalty payments. No definition available.
|
| X | ||||||||||
- Definition Royalty percentage. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
| X | ||||||||||
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|